Boehringer and Lon­za ques­tion the fu­ture of FDA's reg­u­la­tion of AI in man­u­fac­tur­ing

The FDA opened the floor for com­ments on its dis­cus­sion pa­per on the use of AI in drug man­u­fac­tur­ing, with in­ter­est groups and man­u­fac­tur­ers in the US and Eu­rope sub­mit­ting tweaks to the agency.

The dis­cus­sion pa­per on AI in drug man­u­fac­tur­ing fo­cused on is­sues like cloud ap­pli­ca­tions for da­ta, the need for more clar­i­ty about how AI is sub­ject to reg­u­la­to­ry over­sight, and the need for val­i­dat­ing AI mod­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER